Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Capecitabine in Women With Operable Breast Cancer

This study has been terminated.
(Slow accrual)
Sponsor:
Collaborators:
Hoffmann-La Roche
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Information provided by (Responsible Party):
Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00148720
First received: September 7, 2005
Last updated: November 9, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Publications: